ACZONE (dapsone) by Almirall. Approved for sulfone [epc]. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ACZONE (dapsone) is a topical sulfone antibiotic gel approved in 2016 for acne vulgaris and other dermatologic conditions. It acts through bactericidal and bacteriostatic mechanisms, though its exact action in some indications remains unclear. The drug is used across multiple off-label dermatologic and systemic conditions, with broad clinical application.
ACZONE is in peak lifecycle with modest Medicare Part D penetration; commercial team size likely small relative to branded dermatology portfolio.
Sulfone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
Phototoxicity Test of Dapsone Gel in Healthy Volunteers
Dermal Tolerability of Dapsone Gel in Healthy Volunteers
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
Worked on ACZONE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moACZONE offers stable career positioning in a niche, zero-competitive-pressure topical dermatology market managed by Almirall; however, minimal market visibility (96 Part D claims, $89K annual spend) and absence of active trials suggest limited growth momentum and smaller team infrastructure. Professionals should expect focused brand management and MSL support with emphasis on specialty dermatology relationships rather than broad primary care reach.